Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

D. Smith, Bryan; D. Kaufman, Michael; B. Leary, Cynthia; A. Turner, Benjamin; Wise, Scott; Mi Ahn, Yu; J Booth, R; M. Caldwell, Timothy; L. Ensinger, Carol; M. Hood, Molly; Lu, Wei-Ping; W. Patt, Tristan; C. Patt, William; J. Rutkoski, Thomas; Samarakoon, T.; Telikepalli, Hanumaiah; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen; Chun, Lawrence; Stewart, Lance; Clare, Michael; L. Flynn, Daniel

doi:10.1158/1535-7163.mct-14-1105

Public

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Published in Molecular Cancer Therapeutics • Aug 18, 2015

Authors:

Bryan D. Smith

Michael D. Kaufman

Cynthia B. Leary

Abstract

Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and micr...

Subject

Angiogenesis

Angiopoietin receptor

Cancer research

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!